| Monotherapy | Boost | Total | p value |
---|---|---|---|---|
(n = 155) | (n = 63) | (n = 218) | ||
Age (year) | Â | Â | Â | Â |
mean ± SD | 68.1 ± 6.6 | 70.3 ± 6.2 | 68.7 ± 6.5 | 0.023 § |
PSA at diagnosis (ng/mL) | Â | Â | Â | Â |
mean ± SD | 7.2 ± 2.4 | 12.5 ± 6.1 | 8.7 ± 4.5 | < 0.001 § |
10 or less | 139 | 22 | 161 | Â |
10-20 | 16 | 34 | 50 | Â |
greater than 20 | 0 | 7 | 7 | < 0.001 ※ |
biopsy Gleason score | Â | Â | Â | Â |
6 or less | 111 | 22 | 133 | Â |
7 | 44 | 32 | 76 | Â |
8-10 | 0 | 9 | 9 | < 0.001 ※ |
clinical T stage | Â | Â | Â | Â |
T1c | 99 | 32 | 131 | Â |
T2a | 51 | 19 | 70 | Â |
T2b | 5 | 6 | 11 | Â |
T2c | 0 | 6 | 6 | < 0.001 ※ |
neoadjuvant/adjuvant ADT | Â | Â | Â | Â |
none | 112 | 37 | 149 | Â |
neoadjuvant (+) | 42 | 18 | 60 | Â |
adjuvant (+) | 0 | 5 | 5 | Â |
both | 1 | 3 | 4 | 0.001 ※ |
IPSS at baseline | Â | Â | Â | Â |
mean ± SD | 8.7 ± 6.9 | 7.2 ± 5.6 | 8.3 ± 6.6 | 0.107 § |
Follow-up period (month) | Â | Â | Â | Â |
mean ± SD | 44.2 ± 14.9 | 38.3 ± 16.2 | 42.5 ± 15.5 | 0.011 § |